Jazz Gains FDA Approval for Gastric Cancer Drug Ziihera, Challenging Roche's Oncology Market

Jazz's stock surged on Tuesday, breaking out of its buy zone, after the FDA approved its drug Ziihera for treating a specific type of gastric cancer. This development signals positive momentum for Jazz as it strives to compete with Roche in the oncology drug market. The approval of Ziihera marks a potential opportunity for the company as it navigates the competitive pharmaceutical landscape.